Diazepam Buccal Film - An Overview

Overview

Diazepam is utilized in combination with other drugs to manage seizures. It belongs to a category of medications known as benzodiazepines and functions by soothing excessive brain activity. The FDA (U.S. Food and Drug Administration) approved it as an oral medication for treating buccal seizures in 1963.

For Patients:

What Are the Clinical Indications for Diazepam Buccal Film?

Diazepam buccal film is clinically indicated for the acute treatment of seizure clusters, which are also known as acute repetitive seizures. This form of medication is mainly used for patients with epilepsy who experience intermittent bouts of increased seizure activity.

What Is the Dosage of Diazepam Buccal Film?

The dosage of Diazepam buccal film for the treatment of seizure clusters is typically determined based on the patient's age and weight.

• For individuals weighing six kilograms (kg) to 10 kg: The recommended dose is five milligrams (mg).

• For individuals weighing 11 kg to 15 kg: The recommended dose is seven mg.

• For individuals weighing 16 kg to 20 kg: The recommended dose is 10 mg.

What Are the Things to Inform the Doctor Before Taking the Drug?

• Liver or kidney disease.

• Respiratory conditions.

• History of drug or alcohol abuse.

• All prescription and over-the-counter medications, vitamins, and herbal supplements.

• Other medications for depression, sedatives, muscle relaxants, or narcotic pain medications.

• Known allergies to Diazepam, other benzodiazepines, or any other medications.

• Breastfeeding.

• Use of alcohol or recreational drugs.

How Is Diazepam Buccal Film Administered?

The maximum dosage and treatment frequency specify that two doses of Diazepam buccal film should not be exceeded for treating a single episode. If a second dose is necessary, it can be given at least four hours after the initial dose. Avoid using Diazepam buccal film to manage more than one episode every five days or more than five episodes per month.

What Are the Side Effects of Diazepam Buccal Film?

• Drowsiness.

• Dizziness.

• Fatigue.

• Muscle weakness.

• Headache.

• Dry mouth.

• Nausea.

• Constipation.

• Confusion.

• Difficulty urinating.

• Frequent urination.

• Changes in sexual desire or function.

Missed Dose:

If a dose of Diazepam buccal film is missed, the individual should take it as soon as possible. However, if it is near the time for the next scheduled dose, skipping the missed dose and continuing with the regular dosing schedule is recommended. Doubling the dose to make up for the missed one should be avoided.

Overdose:

In the event of an overdose of Diazepam buccal film, immediate medical attention should be sought. It is crucial to contact emergency services or a poison control center for guidance on the next steps.

Storage:

Store Diazepam buccal film at room temperature, away from light and moisture. Keep it out of reach of children and pets. Additionally, do not freeze the medication.

For Doctors:

Indication:

Diazepam buccal film is prescribed for the immediate management of intermittent, stereotypical episodes of frequent seizure activity (referred to as seizure clusters or acute repetitive seizures) that differ from a patient's typical seizure pattern in individuals aged two to five years who have epilepsy.

Dose:

The dosage of Diazepam buccal film varies depending on the patient's age and weight. A maximum of 15 mg (milligrams) is given to patients weighing 30 kg.

What Are the Dosing Considerations?

• The dosage varies based on the patient's age and weight. Adjustments may be necessary for pediatric patients to ensure appropriate dosing.

• The dosing regimen should consider the frequency and severity of seizure clusters. Healthcare providers may recommend specific dosing schedules based on individual patient needs.

• Consideration should be given to any comorbidities, concurrent medications, allergies, and other individual patient factors that may impact dosing and treatment outcomes.

What Are the Pharmacological Aspects of Diazepam Buccal Film?

Mechanism Of Action:

Diazepam enhances the effects of GABA (Gamma-Aminobutyric Acid) by binding to specific sites on the GABA-A receptors, which are ligand-gated chloride channels located postsynaptically in the CNS. This binding facilitates the opening of the chloride channels, leading to an influx of chloride ions into the neuron. This hyperpolarizes the neuron, making it less likely to depolarize and fire an action potential, thus inhibiting neuronal excitability.

The net effect of enhanced GABAergic transmission by Diazepam is multifaceted:

• Sedative Effect: By promoting inhibitory neurotransmission in various regions of the brain, particularly the limbic system and reticular activating system, Diazepam induces sedation and promotes relaxation.

• Anxiolytic Effect: Diazepam reduces anxiety and produces anxiolytic effects by dampening the hyperactivity of neurons in the amygdala and other limbic structures involved in the processing of fear and stress responses.

• Muscle Relaxant Effect: Diazepam acts centrally on the spinal cord and brainstem to decrease muscle tone and inhibit spinal reflexes, resulting in muscle relaxation. This effect is particularly useful in conditions involving muscle spasms or spasticity.

• Anticonvulsant Effect: By increasing the inhibitory tone in the CNS, Diazepam raises the seizure threshold and suppresses abnormal neuronal firing, making it effective in the treatment of seizures and seizure clusters.

Pharmacokinetics:

• Following administration, Diazepam undergoes rapid absorption across the buccal mucosa, facilitated by its lipophilic nature, and swiftly enters the bloodstream. Once in circulation, Diazepam is subjected to extensive hepatic metabolism, primarily mediated by the cytochrome P450 enzyme system, particularly the CYP3A4 isoenzyme. This metabolic process results in the formation of several active metabolites, including desmethyldiazepam (also known as nordiazepam), which contribute to the overall pharmacological effects of Diazepam.

• The conversion of Diazepam to its metabolites involves hydroxylation, demethylation, and conjugation reactions, ultimately leading to the formation of pharmacologically active compounds with varying durations of action. Desmethyldiazepam, in particular, exhibits a prolonged half-life compared to Diazepam itself, contributing significantly to the sustained therapeutic effects observed with Diazepam administration.

• The onset of action of Diazepam following buccal administration is typically rapid, with pharmacological effects becoming evident within minutes. Peak plasma concentrations of Diazepam and its metabolites are generally achieved within 30 to 90 minutes post-administration, although this may vary depending on individual patient factors and the specific formulation used.

• The pharmacokinetic profile of Diazepam, characterized by rapid absorption, extensive metabolism, and the formation of active metabolites, underlies its efficacy in managing various clinical conditions, including anxiety, seizures, and muscle spasms. However, the hepatic metabolism of Diazepam also gives rise to variability in individual response and potential drug interactions, necessitating careful consideration of dosing regimens and monitoring for adverse effects in clinical practice.

Pharmacodynamics:

• Enhancement of GABA Activity: Diazepam enhances the effects of gamma-aminobutyric acid (GABA), the principal inhibitory neurotransmitter in the central nervous system (CNS). It binds to specific sites on the GABA-A receptors, which are ligand-gated chloride channels. This leads to an increase in the frequency of chloride channel opening in response to GABA, resulting in neuronal hyperpolarization and inhibition of neuronal excitability.

• Sedative and Anxiolytic Effects: By potentiating GABAergic neurotransmission, diazepam produces sedative and anxiolytic effects. This leads to a reduction in anxiety levels and induction of relaxation, making it useful in the management of anxiety disorders and promoting sleep.

• Muscle Relaxant and Anticonvulsant Effects: Diazepam's augmentation of GABAergic inhibition also manifests in its ability to reduce muscle tone and inhibit spinal reflexes, resulting in muscle relaxation. Additionally, by increasing the threshold for neuronal excitation, Diazepam exerts anticonvulsant effects, making it effective in the treatment of seizures and seizure clusters.

• Amnesic Effects: Diazepam can impair memory and cognitive function, particularly at higher doses. This property is utilized in medical settings for its preoperative amnesic effects and certain procedures requiring sedation.

• Potential for Tolerance, Dependence, and Withdrawal: Chronic use of Diazepam can lead to the development of tolerance, dependence, and withdrawal symptoms upon discontinuation. This is due to adaptive changes in the GABAergic system and neurotransmitter receptor downregulation.

Clinical Studies And Efficacy:

• The safety and effectiveness of Diazepam buccal film in pediatric patients aged two to five years were supported by evidence from adequate and well-controlled studies of diazepam rectal gel in adults.

• The evidence included studies of diazepam rectal gel in adults and pediatric patients, bioavailability studies comparing Diazepam buccal film with diazepam rectal gel in adults, pharmacokinetic data from adults and pediatric patients, and an open-label safety study of Diazepam buccal film in patients aged two to five.

• The effectiveness of Diazepam rectal gel, which served as a basis for assessing Diazepam buccal film, was established in clinical studies involving pediatric patients aged two years and older and adults experiencing seizure clusters or acute repetitive seizures distinct from their usual seizure pattern.

• A randomized, double-blind study compared sequential doses of Diazepam rectal gel and placebo in pediatric patients aged two years and older and adults with appropriate seizure profiles. The study evaluated primary outcomes of seizure frequency, severity, and overall seizure assessment.

• Patients treated with Diazepam rectal gel exhibited significantly fewer seizures compared to those receiving a placebo. Most patients treated with Diazepam rectal gel were seizure-free during the observation period. Caregivers and investigators rated diazepam rectal gel as more effective than placebo based on visual analog scales and clinical assessments.

• A gender analysis revealed a statistically significant difference in treatment response, with females showing a greater response to Diazepam rectal gel than males.

What Are the Contraindications of Diazepam Buccal Film?

Hypersensitivity to diazepam, such as allergic reactions and acute narrow-angle glaucoma, are contraindications for the use of this medication.

Warnings and Precautions:

• Risks from Concomitant Use with Opioids: Using Diazepam buccal film along with opioids can lead to severe sedation, respiratory depression, coma, and even death. Therefore, simultaneous prescription of Diazepam buccal film and opioids should be limited to cases where other treatment options are insufficient. Observational studies have shown that combining opioid analgesics with benzodiazepines increases the risk of drug-related mortality compared to using opioids alone. If using Diazepam buccal film with opioids is deemed necessary, the lowest effective doses and shortest durations should be prescribed, with close monitoring for signs of respiratory depression and sedation.

• Dependence and Withdrawal Reactions After Use of Diazepam Buccal Film More Frequently Than Recommended: Using Diazepam buccal film more frequently than recommended can lead to dependence, and abrupt discontinuation or rapid dosage reduction may precipitate withdrawal reactions, including life-threatening seizures. Gradual tapering of the dose is recommended for patients using Diazepam buccal film more frequently than prescribed.

• Central Nervous System (CNS) Depression: Diazepam buccal film can cause CNS depression, leading to drowsiness. Careful consideration should be given to potential CNS depression when Diazepam buccal film is used concurrently with alcohol or other CNS depressants.

• Suicidal Behavior and Ideation: Patients treated with Diazepam buccal film should be monitored for suicidal thoughts or behavior, as antiepileptic drugs, including diazepam, may increase the risk of such events. The risk of suicidal thoughts or behavior should be balanced against the risk of untreated illness, with careful consideration given to the patient's circumstances.

• Glaucoma: Diazepam buccal film may increase intraocular pressure in patients with glaucoma. It should be used cautiously in patients with open-angle glaucoma and is contraindicated in those with narrow-angle glaucoma.

• Neonatal Sedation and Withdrawal Syndrome: Unapproved use of Diazepam buccal film during late pregnancy can result in sedation or withdrawal symptoms in neonates. Neonates exposed to diazepam during pregnancy or labor should be monitored for signs of sedation or withdrawal and managed accordingly.

• Risk of Serious Adverse Reactions in Infants Due to Benzyl Alcohol Preservative: Diazepam buccal film is not approved for use in neonates or infants. Serious adverse reactions, including "gasping syndrome," can occur in neonates treated with benzyl alcohol-preserved drugs like Diazepam buccal film. Neonates exposed to diazepam during pregnancy or labor should be monitored for signs of adverse reactions.

Specific Considerations

• Pregnancy: Neonates exposed to benzodiazepines late in pregnancy may experience sedation and neonatal withdrawal symptoms. Human studies show no clear association between benzodiazepines and significant birth defects. Animal studies suggest potential risks of fetal malformations and neurobehavioral effects with diazepam use during pregnancy.

• Lactation: Diazepam is excreted in human milk, and there have been reports of sedation and poor feeding in breastfed infants. Consideration should be given to the benefits of breastfeeding alongside the maternal need for Diazepam buccal film and its potential effects on the infant.

• Pediatric Use: The safety and efficacy of Diazepam buccal film have been established in pediatric patients aged two to five years. It is not approved for use in neonates or infants. Caution is advised due to potential CNS depression in neonates and severe adverse reactions seen in premature infants exposed to benzyl alcohol-preserved drugs.

• Geriatric Use: Diazepam clearance decreases with age, increasing elimination half-life in elderly patients. Caution is recommended in elderly patients, with dosage adjustments to minimize the risk of ataxia or oversedation.

• Respiratory Function: Diazepam buccal film should be used cautiously in patients with compromised respiratory function due to concurrent diseases or neurologic damage.